dvax-8k_20151008.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):   October 8, 2015

 

Dynavax Technologies Corporation

(Exact name of registrant as specified in its charter)

 

Commission File Number:  001-34207

 

Delaware

  

33-0728374

(State or other jurisdiction

of incorporation)

  

(IRS Employer

Identification No.)

2929 Seventh Street, Suite 100

Berkeley, CA 94710-2753

(Address of principal executive offices, including zip code)

(510) 848-5100

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

 

Item 8.01.    Other Events

On October 8, 2015, Dynavax Technologies Corporation issued a press release titled "Dynavax Initiates Immuno-Oncology Clinical Trial Evaluating SD-101 in Combination with Merck’s Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab)." A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

 

Item 9.01.    Financial Statements and Exhibits

(d) Exhibits. The following exhibit is furnished herewith:

99.1 Press Release, dated October 8, 2015, titled "Dynavax Initiates Immuno-Oncology Clinical Trial Evaluating SD-101 in Combination with Merck’s Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab)"

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

Dynavax Technologies Corporation

Date: October 8, 2015

 

 

 

By:

 

/s/  DAVID JOHNSON

 

 

 

 

 

David Johnson

 

 

 

 

 

Vice President

 

 

 

EXHIBIT INDEX

 

Exhibit No.

 

Description

 

 

 

 

 

EX-99.1

 

Press Release, dated October 8, 2015, titled “Dynavax Initiates Immuno-Oncology Clinical Trial Evaluating SD-101 in Combination with Merck’s Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab)”